First Marketing Authorization secured by Venus Remedies for Plerixafor in any market Advances the company's shift into higher value specialty injectables across regulated markets Plerixafor is a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma Venus Remedies Limited (NSE:
Approval marks Venus Remedies’ entry into Argentina for Ceftriaxone, taking total global MAs for the antibiotic to 39 Argentina is the 4th-largest pharmaceutical market in Latin America, valued at approximately US$7.3 billion in 2023 Approval strengthens Venus Remedies’ growing international anti infective portfolio amid rising burden of infectious
The latest disbursement underscores the Company’s role in strengthening India’s domestic pharmaceutical manufacturing ecosystem Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has received its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals, representing 75 percent
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has secured the marketing authorization from the Indonesian regulatory authority
The approvals strengthen India’s position as a reliable supplier of advanced pharmaceuticals across ASEAN markets where Venus Remedies already exports more than 374 products. Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the 10 leading fixed-dosage injectable manufacturers in the world, has secured new marketing authorizations
VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for VRP-034 included up to 70% reduction in nephrotoxicity compared to marketed PMB The QIDP
Marketing approvals for bortezomib from Philippines and carboplatin from Morocco will enable the company to enhance its presence in ASEAN, African regions Venus Remedies Ltd, a prominent oncology drug manufacturer, has secured marketing authorizations for two key cancer drugs, enhancing its global reach. The approvals
The UNICEF order for ceftriaxone supply is an endorsement of Venus Remedies’ exceptional quality standards and its position as a trusted partner in global healthcare supply chains The company also secures a mandate from the world's oldest international public health agency for supplying essential
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy Venus Remedies is among the largest Indian exporters of these drugs Ukraine is among the largest countries in Europe and its pharmaceutical market has been witnessing
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF This achievement is an endorsement of Venus Remedies' commitment to delivering top-quality pharmaceutical products worldwide Venus Remedies Limited, a leading global pharmaceutical company, has recently secured
